Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa., PMID:40502542
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates., PMID:40500332
Nanobodies and their derivatives: pioneering the future of cancer immunotherapy., PMID:40474230
[Screening and characterization of camelid-derived nanobodies against hemoglobin]., PMID:40328713
[Construction and characterization of single-framework fully synthetic nanobody libraries]., PMID:40328712
Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602
CD7-Targeted Cytotoxic Potency of Diphtheria Toxin- and Ricin-Based Immunotoxins in Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia., PMID:40317108
New anti-TNF biologics in RA: What is new and what is old?, PMID:40180877
Development of an Anti-Zearalenone Nanobody Phage Display Library and Preparation of Specific Nanobodies., PMID:40136411
Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model., PMID:40088168
Development and Preclinical Evaluation of [64Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics., PMID:40015924
Nanobody-based drug delivery systems for cancer therapy., PMID:39993634
A simple and effective method to remove pigments from heterologous secretory proteins expressed in Pichia pastoris., PMID:39883296
Peptidisc-Assisted Hydrophobic Clustering Toward the Production of Multimeric and Multispecific Nanobody Proteins., PMID:39810388
Framework Nucleic Acid-Nanobody Fusion Probe-Based Pharmacokinetics Modulation and Analysis for Efficient Positron Emission Tomography Imaging., PMID:39714093
Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation., PMID:39637990
Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity., PMID:39603436
A Diketopinic Reagent for the Reversible Bioconjugation to Arginine Residues on Native Antibodies., PMID:39432883
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration., PMID:39397258
A Biparatopic Intrabody Renders Vero Cells Impervious to Ricin Intoxication., PMID:39297955
Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies., PMID:39036071
Oriented immobilization of nanobodies using SpyCatcher/SpyTag significantly enhances the capacity of affinity chromatography., PMID:38905946
NFC Smartphone-Based Electrochemical Microfluidic Device Integrated with Nanobody Recognition for C-Reactive Protein., PMID:38877998
Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy., PMID:38766114
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer., PMID:38755613
Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy., PMID:38737471
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins., PMID:38691205
Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers., PMID:38580333
Sequence-based design and construction of synthetic nanobody library., PMID:38548653
Development of a double antibody sandwich ELISA method for the quantitative detection of serum C-reactive protein based on nanobody., PMID:38521472
Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species., PMID:38352869
An Albumin-Holliday Junction Biomolecular Modular Design for Programmable Multifunctionality and Prolonged Circulation., PMID:38231391
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents., PMID:38183712
Diving deep into fish allergen immunotherapy: Current knowledge and future directions., PMID:38165149
Crystal structure of human serum albumin in complex with megabody reveals unique human and murine cross-reactive binding site., PMID:38152025
Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration., PMID:38142486
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer., PMID:37932752
[Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 mg Syringes for S.C. Injection), the first Nanobody® compound in Japan]., PMID:37914330
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis., PMID:37909264
Alpha hemolysin of E. coli induces hemolysis of human erythrocytes independently of toxin interaction with membrane proteins., PMID:37820991
The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice., PMID:37730142
Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody., PMID:37620930
"Fluorescence-wavelength" label-free POCT tandem with "fluorescence-photothermal" nanobody-immunosensor for detecting BSA and β-lactoglobulin., PMID:37552900
Design of Beta-2 Microglobulin Adsorbent Protein Nanoparticles., PMID:37509158
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis., PMID:37431762
A few good reasons to use nanobodies for cancer treatment., PMID:37366246
Enhanced in Vivo Blood Brain Barrier Transcytosis of Macromolecular Cargo Using an Engineered pH-sensitive Mouse Transferrin Receptor Binding Nanobody., PMID:37333358
Albumin binding improves nanobody pharmacokinetics for dual-modality PET/NIRF imaging of CEACAM5 in colorectal cancer models., PMID:37191678
Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor., PMID:37185766
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials., PMID:37055803
For research use only. Not for human or drug use.
